Targeting specific kinases to treat acute myelogenous leukemia
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
This study is looking at a new treatment for acute myelogenous leukemia (AML) using a special drug called TL02-59, which targets certain active proteins in the cancer cells, and it aims to find out how well it works and if there are any reasons it might not work for some patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10740923 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for acute myelogenous leukemia (AML) by focusing on a small molecule inhibitor called TL02-59. The study aims to understand how this compound works against AML cells, particularly those with high levels of specific kinases that are often overactive in this cancer. By testing this drug on patient-derived bone marrow samples and in mouse models, the researchers hope to determine its effectiveness and potential resistance mechanisms. Patients may benefit from a more targeted therapy that could improve treatment outcomes for AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with acute myelogenous leukemia.
Not a fit: Patients with other types of leukemia or those who are not adults may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and targeted treatment option for patients with acute myelogenous leukemia.
How similar studies have performed: Previous research has shown promising results with targeted therapies in similar contexts, indicating potential for success with this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Smithgall, Thomas E. — University of Pittsburgh at Pittsburgh
- Study coordinator: Smithgall, Thomas E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.